CA184-095_3 | R Documentation |
Kaplan-Meier digitized data from CA184-095, figure 3 (PMID 28034081). A reported sample size of 602 for a primary endpoint of OS in prostate cancer.
`CA184-095_3`
A data frame of 602 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (ipilimumab, placebo) | |
Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol 2017; 35: 40–7.
summary(`CA184-095_3`)
kmplot(`CA184-095_3`)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.